Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$4.64
-0.14 (-2.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-336.7M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-117.6%
↓Gross Margin
84.8%
↑Debt/Equity
1.85
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+43.3%
FCF CAGR
—
FCF margin
-148.6%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $141.8M · net income $-241.6M · FCF $-210.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $141.8M | $141.8M | $130.3M | $90.8M | $48.2M |
| Net Income | $-241.6M | $-241.6M | $-440.7M | $-421.1M | $-220.3M |
| EBITDA | $-217.7M | $-217.7M | $-408.7M | $-390.4M | $-195.9M |
| EPS | -0.37 | -0.37 | -0.67 | -0.64 | -0.38 |
| Gross Margin | 84.8% | 84.8% | 82.8% | 81.6% | 81.7% |
| Operating Margin | -172.3% | -172.3% | -335.1% | -480.2% | -481.4% |
| Net Margin | -170.4% | -170.4% | -338.3% | -463.9% | -457.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.85 | 1.85 | 0.69 | 0.27 | 0.19 |
| Current Ratio | 2.77 | 2.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-210.7M | $-210.7M | $-448.1M | $-336.7M | $-252.2M |
| Returns | |||||
| ROE | -117.6% | -117.6% | -100.4% | -50.5% | -18.1% |
| Valuation | |||||
| P/B | 14.74 | 14.74 | 7.03 | 5.03 | 4.25 |
| Growth & Yield | |||||
| Revenue Growth | 8.8% | 8.8% | 43.5% | 88.3% | — |
| EPS Growth | 44.8% | 44.8% | -4.7% | -68.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.67 → -0.37
Residual
-23.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.